Premium
Impact of body‐surface area on patients’ outcome in younger adults with acute myeloid leukemia
Author(s) -
Cahu Xavier,
Carré Martin,
Recher Christian,
Pigneux Arnaud,
HunaultBerger Mathilde,
Vey Norbert,
Chevallier Patrice,
Delaunay Jacques,
Gyan Emmanuel,
Lioure Bruno,
Bonmati Caroline,
Himberlin Chantal,
Hicheri Yosr,
Guillerm Gaelle,
Didier Bouscary,
Larosa Fabrice,
OjedaUribe Mario,
Bernard Marc,
Bene Marie C.,
Ifrah Norbert,
Cahn JeanYves
Publication year - 2017
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/ejh.12850
Subject(s) - body surface area , cytarabine , medicine , chemotherapy , myeloid leukemia , leukemia , clinical trial , oncology , gastroenterology , surgery
Objectives Anthracyclines and cytarabine are cornerstones for intensive chemotherapy in acute myeloid leukemia (AML). The goals of this study were to comprehensively assess deviations from theoretical doses and the impact of body‐surface area (BSA) on patients’ characteristics, physicians’ strategy, dose adjustment, and clinical outcome. Methods The GOELAMS 2001 phase III trial included 823 AML patients below 60 years of age. In the course of treatment, anthropomorphic parameters and chemotherapy doses were prospectively registered. Results Very high BSA (≥2.15 m 2 ) was the factor most significantly associated with the physician's decision to reduce chemotherapy doses during induction and postremission therapy. Despite similar AML characteristics and therapeutic strategies, the very high BSA group exhibited a significantly worse survival (5‐years OS of 27%) compared to the low (BSA≤1.5 m 2 ), intermediate (1.5 m 2